CLINICAL TRIAL SUMMARY

MDACC Study No:2009-0833 (clinicaltrials.gov NCT No: NCT01092182)
Title:PHASE II STUDY OF DOSE-ADJUSTED EPOCH+/- RITUXIMAB IN ADULTS
WITH UNTREATED BURKITT LYMPHOMA, c-MYC POSITIVE DIFFUSE LARGE BCELL LYMPHOMA AND PLASMABLASTIC LYMPHOMA
Principal Investigator:Michelle A. Fanale
Treatment Agent:Cyclophosphamide; Doxorubicin; Etoposide; Prednisone; Rituximab; Vincristine
Study Status:Open
Study Description:The goal of this clinical research study is to learn if and how long etoposide,
prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab can help
to control Burkitt lymphoma, aggressive c-myc positive diffuse large B-cell or
Plasmablastic lymphoma. The safety of this drug combination will also be
studied. Some participants may also receive methotrexate as part of the
investigational therapy.

Hide details for General InformationGeneral Information

Disease Group:Lymphoma
Phase of Study:Phase II
Treatment Agents:Cyclophosphamide
Doxorubicin
Etoposide
Prednisone
Rituximab
Vincristine
Treatment Location:Both at MDACC & outside MDACC at one or more Collaborating Sites or Institutions
Estimated Length of Stay in Houston:q 21 days for 6 days
Supported By:Genentech
Return Visit:Pre-Therapy, Pre Cycles 1-6, BIW Cycles 1-6, Pre Cycle 3, Pre Cycle 5 (high
risk), Post Cycle 6 (high risk), Follow Up visits
Home Care:None


Hide details for Study Contact InformationStudy Contact Information

Physician Name:Michelle A. Fanale
Dept:Lymphoma/Myeloma
For Clinical Trial Enrollment:713-792-2860
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults